BPC-157 VEGFR2 Research: Cell Biology Pathway Studies
Peptide BPC-157 for Cell Biology Pathway Investigation
BPC-157 represents a synthetic pentadecapeptide research compound extensively studied in cell-based assay formats for its interaction with vascular endothelial growth factor receptor 2 (VEGFR2) pharmacology. This research peptide demonstrates complex molecular interactions involving focal adhesion kinase (FAK)/paxillin signalling cascades and nitric oxide synthase pathway modulation. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
The peptide sequence maintains stability in cell culture media and exhibits reproducible pharmacological profiles across multiple endothelial cell line models. Research applications focus on angiogenesis pathway characterisation, endothelial cell migration assays, and vascular signalling network analysis in standardised laboratory environments.
Receptor Pharmacology and Mechanism of Action
VEGFR2 Receptor Binding Characteristics
BPC-157 demonstrates selective interaction with VEGFR2 through competitive radioligand binding assays and functional cell-based receptor activation studies. Saturation binding experiments in human umbilical vein endothelial cell (HUVEC) models reveal concentration-dependent receptor occupancy with measurable equilibrium dissociation constants. The peptide exhibits partial agonist properties at VEGFR2, generating submaximal receptor activation compared to native VEGF ligands.
Receptor pharmacology studies utilise tyrosine kinase phosphorylation assays to quantify VEGFR2 activation kinetics. Time-course experiments demonstrate rapid receptor phosphorylation within 5-15 minutes of peptide exposure, followed by sustained signalling over 2-4 hour observation periods in controlled cell culture systems.
FAK/Paxillin Signalling Network Engagement
Downstream of VEGFR2 activation, BPC-157 triggers focal adhesion kinase phosphorylation at specific tyrosine residues, particularly Tyr397 and Tyr861. Western blot analysis reveals concentration-dependent FAK activation with EC50 values consistent across multiple endothelial cell model systems. Paxillin phosphorylation occurs secondary to FAK activation, creating focal adhesion complex formation measurable through immunofluorescence microscopy techniques.
Cell migration assays demonstrate functional consequences of FAK/paxillin pathway activation. Scratch wound assays and Boyden chamber migration studies quantify directional cell movement responses to BPC-157 exposure in standardised assay formats. These functional readouts correlate directly with upstream signalling pathway activation measurements.
Nitric Oxide Synthase Pathway Modulation
eNOS Enzyme Kinetics
BPC-157 influences endothelial nitric oxide synthase (eNOS) activity through both direct enzyme interaction and upstream signalling pathway modulation. Enzyme kinetic studies reveal altered Michaelis-Menten parameters in the presence of BPC-157, suggesting allosteric enzyme regulation rather than competitive inhibition mechanisms.
Phosphorylation analysis of eNOS at Ser1177 demonstrates increased enzyme activation following BPC-157 treatment in endothelial cell cultures. This phosphorylation event correlates with enhanced nitric oxide production measurable through DAF-FM fluorescence assays and Griess reagent colorimetric detection methods.
cGMP Signalling Cascade
Nitric oxide production leads to downstream cyclic guanosine monophosphate (cGMP) elevation in target cell populations. Enzyme-linked immunosorbent assays quantify cGMP accumulation following BPC-157 exposure, revealing dose-dependent responses with characteristic sigmoidal concentration-response curves. Peak cGMP levels typically occur 30-60 minutes post-treatment in standardised cell culture conditions.
Experimental Methodologies and Cell Model Systems
Primary Cell Culture Applications
Research applications employ primary endothelial cell isolations from multiple tissue sources to validate BPC-157 pharmacological profiles. Human coronary artery endothelial cells, human dermal microvascular endothelial cells, and bovine aortic endothelial cells serve as complementary model systems for receptor pharmacology characterisation.
Cell viability assays confirm biocompatibility across tested concentration ranges, typically 1 nM to 10 μM, with minimal cytotoxicity observed in standard MTT and LDH release assays. Optimal experimental concentrations for pathway analysis range from 10-1000 nM based on receptor binding saturation studies.
Advanced Assay Techniques
High-content imaging systems enable real-time monitoring of cellular responses to BPC-157 treatment. Time-lapse microscopy captures dynamic changes in cell morphology, focal adhesion formation, and migration patterns under controlled environmental conditions. Automated image analysis quantifies multiple endpoint parameters simultaneously across large experimental datasets.
Research Summary
BPC-157 demonstrates multifaceted receptor pharmacology through VEGFR2 activation, FAK/paxillin signalling engagement, and nitric oxide pathway modulation in established cell culture models. The peptide exhibits concentration-dependent responses across multiple signalling networks with reproducible pharmacological profiles. These mechanistic insights support continued investigation of BPC-157 in angiogenesis research applications and vascular biology studies using standardised in vitro experimental approaches.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Hexarelin
TB-500
Epithalon
Ipamorelin
Tirzepatide
CJC-1295 DAC
PT-141
Semaglutide
Selank
BPC-157
Sermorelin
Melanotan 2
IGF LR3
Tesamorelin
AICAR
IGF-DES
GHRP 2
Albuterol
Tamoxifen
Letrozole
Clomiphene
Tadalafil
Clenbuterol
Anastrozole
Finasteride
Exemestane
Sildenafil
Yohimbine
Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
Already a customer? Sign In
Create Account
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML